Search

Your search keyword '"Kandela, Irawati"' showing total 259 results

Search Constraints

Start Over You searched for: Author "Kandela, Irawati" Remove constraint Author: "Kandela, Irawati"
259 results on '"Kandela, Irawati"'

Search Results

1. Targeting EphA2 in Bladder Cancer Using a Novel Antibody-Directed Nanotherapeutic.

2. Ecoresorbable and bioresorbable microelectromechanical systems

3. Photocurable bioresorbable adhesives as functional interfaces between flexible bioelectronic devices and soft biological tissues

6. Bioresorbable photonic devices for the spectroscopic characterization of physiological status and neural activity

8. Bioresorbable pressure sensors protected with thermally grown silicon dioxide for the monitoring of chronic diseases and healing processes

10. Data from Posttranslational Regulation of the Exon Skipping Machinery Controls Aberrant Splicing in Leukemia

11. Supplementary Table 10 from Posttranslational Regulation of the Exon Skipping Machinery Controls Aberrant Splicing in Leukemia

12. Supplementary Table 8 from Posttranslational Regulation of the Exon Skipping Machinery Controls Aberrant Splicing in Leukemia

13. Supplementary Table 7 from Posttranslational Regulation of the Exon Skipping Machinery Controls Aberrant Splicing in Leukemia

14. Supplementary Table 2 from Posttranslational Regulation of the Exon Skipping Machinery Controls Aberrant Splicing in Leukemia

15. Supplementary Table 6 from Posttranslational Regulation of the Exon Skipping Machinery Controls Aberrant Splicing in Leukemia

16. Supplementary Table 9 from Posttranslational Regulation of the Exon Skipping Machinery Controls Aberrant Splicing in Leukemia

17. Supplementary Table 4 from Posttranslational Regulation of the Exon Skipping Machinery Controls Aberrant Splicing in Leukemia

18. Supplementary Table 5 from Posttranslational Regulation of the Exon Skipping Machinery Controls Aberrant Splicing in Leukemia

19. Supplementary Figures S1-15 from Posttranslational Regulation of the Exon Skipping Machinery Controls Aberrant Splicing in Leukemia

20. Supplementary Table 3 from Posttranslational Regulation of the Exon Skipping Machinery Controls Aberrant Splicing in Leukemia

24. Supplementary Table 2 from USP7 Cooperates with NOTCH1 to Drive the Oncogenic Transcriptional Program in T-Cell Leukemia

26. Figures S1-17 plus legends from USP7 Cooperates with NOTCH1 to Drive the Oncogenic Transcriptional Program in T-Cell Leukemia

27. Supplementary Table 1 from USP7 Cooperates with NOTCH1 to Drive the Oncogenic Transcriptional Program in T-Cell Leukemia

28. Table S3. Gene Set Enrichment Analysis (GSEA) C2 gene sets. from Proteasomal Inhibition by Ixazomib Induces CHK1 and MYC-Dependent Cell Death in T-cell and Hodgkin Lymphoma

29. Data from Proteasomal Inhibition by Ixazomib Induces CHK1 and MYC-Dependent Cell Death in T-cell and Hodgkin Lymphoma

30. Table S2. Gene Set Enrichment Analysis (GSEA) C5 GO gene sets. from Proteasomal Inhibition by Ixazomib Induces CHK1 and MYC-Dependent Cell Death in T-cell and Hodgkin Lymphoma

31. Figure S1. Quantitative RT-PCR validation of ixazomib genes. from Proteasomal Inhibition by Ixazomib Induces CHK1 and MYC-Dependent Cell Death in T-cell and Hodgkin Lymphoma

32. Supplementary Legends from Proteasomal Inhibition by Ixazomib Induces CHK1 and MYC-Dependent Cell Death in T-cell and Hodgkin Lymphoma

33. Table S4. Key genes involved with anti-proteasomal response in L428 cells. from Proteasomal Inhibition by Ixazomib Induces CHK1 and MYC-Dependent Cell Death in T-cell and Hodgkin Lymphoma

34. Figure S3. Inhibition of histone acetyl transferase (HAT). from Proteasomal Inhibition by Ixazomib Induces CHK1 and MYC-Dependent Cell Death in T-cell and Hodgkin Lymphoma

35. Table S1. Common upstream regulators. from Proteasomal Inhibition by Ixazomib Induces CHK1 and MYC-Dependent Cell Death in T-cell and Hodgkin Lymphoma

36. Table S5. DAVID functional classification of ixazomib genes. from Proteasomal Inhibition by Ixazomib Induces CHK1 and MYC-Dependent Cell Death in T-cell and Hodgkin Lymphoma

37. Figure S2. Network representation of Gene Set Enrichment Analysis (GSEA) for Biological pathways. from Proteasomal Inhibition by Ixazomib Induces CHK1 and MYC-Dependent Cell Death in T-cell and Hodgkin Lymphoma

39. Oncogenic deubiquitination controls tyrosine kinase signaling and therapy response in acute lymphoblastic leukemia

41. Data

45. Study 19: Registered Report Additional Materials

47. Data

49. Figures

Catalog

Books, media, physical & digital resources